Skip to main content
Signal8
Launch Terminal

Inmune Bio, Inc. (INMB)

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

INmune Bio, Inc. logo

INmune Bio, Inc.

NASDAQ:INMBHealthcare
-9.38%$1.45
AH$1.43-1.38%vs close
Mkt Cap$40.24M
Float24.75M
O/S27.75M
Vol
$ Vol
RVOL
Inst Own15.6%
Earnings
Dilution
INmune Bio, Inc. logoNASDAQ:INMB$1.45-9.38%
Upcoming Catalysts
Phase Distribution
7 lead-sponsored trials·0 active·3 completed
Phase 12
Phase 1/21
Phase 23
Phase 2/31

Trials need funding. See this company's dilution risk and cash position.

Recent Deals
  • Uniphar Durbin Ireland LimitedCOLLAB
    Oct 21, 2026
    Ebstrocel™
Clinical Trials
Status
Phase
  • Phase 2/3
    Terminated

    INB03 for the Treatment of Pulmonary Complications From COVID-19

    INB03, Placebo

    COVID-19

    Enrollment
    79
    Start
    Oct 2020
    Primary Completion
    Oct 2021
    Completion
    Nov 2021
    NCT04370236
  • Phase 2
    Completed

    A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation

    XPro1595, PlaceboFAST TRACK

    Alzheimer Disease, Dementia +8

    Enrollment
    207
    Start
    Feb 2022
    Primary Completion
    May 2025
    Completion
    May 2025
    NCT05318976
  • Phase 2
    Withdrawn

    Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

    XPro1595, PlaceboFAST TRACK

    Mild Cognitive Impairment (MCI), Alzheimer Disease +7

    Enrollment
    0
    Start
    Jun 2023est.
    Primary Completion
    Oct 2023est.
    Completion
    Oct 2023est.
    NCT05321498
  • Phase 2
    Terminated

    An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

    XPro1595FAST TRACK

    Alzheimer Disease, Dementia +7

    Enrollment
    11
    Start
    Feb 2023
    Primary Completion
    Jun 2024
    Completion
    Jul 2024
    NCT05522387
  • Phase 1/2
    Completed

    Study of INKmune in Patients With mCRPC (CaRe Prostate)

    INKmune

    Cancer, Metastatic Castration-resistant Prostate Cancer +1

    Enrollment
    12
    Start
    Nov 2023
    Primary Completion
    Sep 2025
    Completion
    Sep 2025
    NCT06056791
  • Phase 1
    Completed

    A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's

    XPro1595FAST TRACK

    Alzheimer Disease

    Enrollment
    20
    Start
    Nov 2019
    Primary Completion
    Jun 2021
    Completion
    Sep 2021
    NCT03943264
  • Phase 1
    Terminated

    A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML

    INKmune

    Cancer, MDS-EB +3

    Enrollment
    2
    Start
    Jun 2020
    Primary Completion
    Mar 2024
    Completion
    Apr 2024
    NCT05933070
Search ClinicalTrials.gov for “Inmune Bio”